Flyte Aviation, Inc.

Catheter Precision Announces New FDA 510(k) Clearance for its VIVO System, Enabling Use in a Broader Patient Population

Catheter Precision, a wholly owned subsidiary of Flyte Aviation (VJET), received FDA 510(k) clearance for expanded labeling of its VIVO system. The clearance enables use in a broader patient population — individuals with structural heart disease undergoing catheter ablation for monomorphic ventricular tachycardia. The label expansion widens VIVO's commercial addressable market, though no revenue figures or adoption timelines were disclosed.

•1d ago

Flyte Aviation Expands International Operations to Canada

Flyte Aviation received approval from Transport Canada to operate flights in and out of Canada, marking its first international market expansion beyond its U.S. network and Caribbean destinations. Initial routes are expected to connect north and northeast US urban areas with Toronto, Montreal and Ottawa, subject to airport, customs and operational requirements. The company also disclosed estimated preliminary record Q3 2026 revenue of approximately $2.1 million, up 110% quarter-over-quarter, with its platform surpassing 20,000 registered users since the late-May direct-to-consumer launch.

•5d ago

Flyte Aviation, One of the Nation’s Largest Vision Jet Operators, Congratulates Cirrus Aircraft on Ten Years of Innovation

Flyte Aviation announced plans to expand its Cirrus Vision Jet fleet from five aircraft to ten by the first quarter of 2027, positioning itself as one of the nation's largest Vision Jet operators. The release doubles as a congratulatory milestone piece marking the Vision Jet's 10th anniversary and Cirrus's 800th-plus deliveries worldwide; Flyte's charter fleet is equipped with Garmin Safe Return Autoland and the Cirrus CAPS parachute system. Flyte expects the expansion to increase revenue, aircraft availability, and regional coverage, with California service planned to begin in Q1 2027 alongside its existing East Coast, Canada, and Bahamas footprint.

•8d ago

Catheter Precision Announces Publication of Comparative Study Showing LockeT Outperforms Abbott’s Perclose Internal Vascular Closure Device

Catheter Precision, a wholly owned subsidiary of Flyte Aviation (NYSE American: VJET), announced the first published comparative study of its LockeT suture retention device versus Abbott's Perclose internal vascular closure device. In the 172-patient peer-reviewed study in The Journal of Interventional Cardiology, LockeT showed a 1.2% cumulative access-site complication rate versus 9.3% for Perclose, and a 0.0% device failure rate versus 4.7%. Both methods delivered similar time to hemostasis and same-day discharge rates. LockeT is an FDA-registered Class 1 device with CE Mark, already selling in the US, Europe and South America.

•12d ago

Flyte Aviation Establishes New B2B Distribution Channel, Launches Partner Portal

Flyte Aviation launched its Flyte Partner Portal, a proprietary B2B platform giving strategic partners dedicated accounts, streamlined booking, and preferred pricing for private aviation. The portal converts partnerships across hospitality, sports, entertainment, and luxury lifestyle — including the Philadelphia 76ers — into a scalable distribution channel the company expects to drive flight volume, customer acquisition, and aircraft utilization. Flyte also reiterated record preliminary Q3 2026 revenue of approximately $2.1 million, up 110% quarter-over-quarter, with its platform user base exceeding 20,000 accounts.

•14d ago

Flyte Aviation Partners with The Philadelphia 76ers

Flyte Aviation signed a multi-year deal naming it the Official Private Aviation Partner of the Philadelphia 76ers. The partnership spans digital and social media, premium hospitality, and fan engagement, including an in-arena "Halftime Flyte Challenge" promotion offering fans private flights. No financial terms were disclosed; the deal is a brand-exposure and customer-acquisition play for the micro-cap aviation platform as it expands its Northeast US footprint.

•20d ago

Flyte Aviation Reports Record Preliminary Third Quarter Revenue of $2.15 Million, Up 110% Quarter Over Quarter

Flyte Aviation reported record preliminary Q3 2026 revenue of approximately $2.15 million, up about 110% from $1.02 million in Q2. Aviation segment revenue rose 150% sequentially to roughly $1.87 million, while MedTech grew 24% YoY to about $280,000; direct-to-consumer revenue surpassed $500,000 in the quarter. The platform's user base jumped 185% since its late-May redesign, adding 13,000+ accounts to exceed 20,000 total users. CEO David Jenkins said the company is adding aircraft and has commenced Caribbean operations, with Canadian permitting nearly complete, supporting growth into 2027. Results are preliminary and unaudited, subject to the upcoming 10-Q.

•22d ago

VTAK Announces Preliminary Second Quarter Record Revenue in Excess of $1 million

Catheter Precision reported preliminary record revenue of $1.04 million for the second quarter of 2026, marking the first time the company has exceeded the $1 million quarterly threshold. The Flyte Vision Jet segment drove the performance with $767,000 in revenue, representing a 61% sequential increase, while the MedTech segment grew 27% year-over-year. Management highlighted that preliminary revenue for the first two weeks of July is already over $400,000 and noted ongoing work with an investment bank regarding strategic alternatives for the MedTech segment.

•3mo ago

Catheter Precision, Inc. Announces Issuance of Two Key Patents

Catheter Precision announced the issuance of European patent No. 3742967 covering its VIVO technology, which uses internal signals from implantable devices to precisely locate ventricular arrhythmias. The company also received a patent related to its Cardionomix portfolio for denoising physiological signals during electrical neuromodulation to treat Acute Decompensated Heart Failure. CEO David Jenkins highlighted that the VIVO technology has completed 10 human patients with early proof of concept, while the STOP-ADHF study of 49 patients showed statistically significant benefits including freedom from CV-related death.

•3mo ago

Flyte Announces Successful Launch of New Direct-to-Consumer Booking Platform

Flyte, a subsidiary of Catheter Precision, launched a digital booking platform and secured over 1,000 new users in the first half of 2026, generating $1.0 million in revenue. The platform leverages AI for pricing and customer acquisition, facilitating 118 flights on a fleet of Cirrus Vision Jets with standardized pricing and no membership fees. Management expects Q2 revenue to reach approximately $760,000, representing a 150% increase quarter-over-quarter, supported by multi-channel marketing and strategic partnerships.

•4mo ago

Flyte Partners with GSE Worldwide and PGA TOUR Professional Emiliano Grillo, Debuted at the 2026 U.S. Open

Flyte, a subsidiary of Catheter Precision, announced a strategic partnership with sports agency GSE Worldwide and PGA TOUR professional Emiliano Grillo during the 2026 U.S. Open. The collaboration aims to showcase Flyte's regional air mobility platform and Cirrus Vision Jet fleet to elite athletes seeking efficient short-haul travel solutions. CEO Marc Sellouk emphasized the alignment between Flyte's services and the demanding travel schedules of professional athletes, signaling a targeted expansion into the sports market.

•4mo ago

Catheter Precision, Inc. Announces Allowance of Key Intellectual Property

Catheter Precision announced the allowance of 11 patents across its heart failure and vascular closure technology portfolios, expanding its IP library to over fifty assets. The vascular closure patents specifically cover the LockeT product, including US patent no. 12,622,686, which is currently marketed in the US and Europe. Management disclosed that the company is currently in discussions regarding the sale of these two technologies, noting that the new patents strengthen the offering for these talks.

•4mo ago

FLYTE EXPANDS STRATEGIC RELATIONSHIP WITH VOLATO BY JOINING VAUNT PLATFORM

Flyte, the regional air mobility subsidiary of Catheter Precision (VTAK), has joined the Vaunt operator network, a private aviation membership platform owned by Volato Group (SOAR). This partnership allows Flyte to market its Cirrus Vision Jet fleet to Vaunt’s growing member base, creating a new channel to monetize repositioning flights and improve aircraft utilization. Vaunt reported annual recurring revenue of $3.6 million, up 162% year-over-year, and is offering members a $1,000 credit to book their first Flyte charter.

•4mo ago

Flyte (VTAK) Makes Strategic Investment in Volato (SOAR)

Catheter Precision’s subsidiary Flyte (VTAK) acquired 2.9 million shares of Volato (SOAR), becoming its largest shareholder with a 7.5% stake. The investment provides SOAR with growth capital and establishes a strategic partnership to explore collaboration across private aviation platforms. VTAK aims to expand its aviation ecosystem, while SOAR leverages the capital for strategic initiatives and its pending acquisition of M2i Global.

•4mo ago

FLYTE ACTIVATES HIGH-FREQUENCY MEMORIAL DAY WEEKEND FLIGHT NETWORK TO CAPTURE SURGING NORTHEAST DEMAND

Flyte, the regional air mobility subsidiary of Catheter Precision (VTAK), has fully activated its Memorial Day flight network across the Northeast corridor. The company is deploying aircraft on high-frequency short-haul routes to Nantucket, the Hamptons, Martha’s Vineyard, and Boston to capture premium demand from travelers avoiding ground congestion. Operations are conducted via its FAA-certified subsidiary Ponderosa Air, LLC, with a target of at least five Cirrus Vision Jets in service for the holiday window.

•5mo ago

CATHETER PRECISION REPORTS 200% REVENUE GROWTH AND COMPLETES TRANSFORMATIVE FLYTE ACQUISITION

Catheter Precision reported Q1 2026 revenue of $432,000, a 200% increase year-over-year, driven by expansion in its medical device segment and the newly acquired Flyte aviation platform. The company’s net loss narrowed significantly to $1.7 million from $4.0 million in the prior year, reflecting improved operating leverage and revenue scaling. The Flyte acquisition contributed immediate traction, achieving a $200,000 monthly revenue run rate within 22 days of post-acquisition operations and expanding its fleet to three aircraft.

•5mo ago

Flyte Increases Capacity and Launches Hiring Initiative as Spirit Airlines Shutdown Disrupts U.S. Air Travel

Flyte, a subsidiary of Catheter Precision (VTAK), announced it is accelerating its planned Vision Jet fleet expansion and launching a hiring initiative aimed at pilots and aviation professionals displaced by the shutdown of Spirit Airlines. The shutdown of Spirit has significantly reduced domestic capacity, leading to higher fares and widespread disruptions, which Flyte believes will drive interest in alternative premium short-haul options. While competitors like JetBlue, Delta, and American Airlines are expected to absorb displaced demand, Flyte is focusing on increasing utilization and expanding route coverage in high-demand regional corridors to serve its existing customer base.

•6mo ago

Flyte Deploys Additional Vision Jets in the Northeast to Capture Surging Summer Demand

Flyte, the regional air mobility subsidiary of Catheter Precision, is expanding its Cirrus Vision Jet fleet to address accelerating summer travel demand in the Northeast. The service expansion targets high-value routes connecting New York City with destinations like the Hamptons, Nantucket, and Martha’s Vineyard, reducing travel time from several hours to 30 to 60 minutes. Flight operations are conducted through Flyte's wholly owned subsidiary, Ponderosa Air, LLC, an FAA-certified Part 135 air carrier.

•6mo ago

Catheter Precision to Attend and Share New Clinical Data at the 47th Annual Heart Rhythm Society Meeting

Catheter Precision will present new clinical data on its VIVO system at the 47th Annual Heart Rhythm Society meeting and announced the acceptance of two peer-reviewed publications for its products. The accepted studies include a LockeT trial involving 139 patients that demonstrated high procedural success, and a VIVO study of 31 patients that showed improved accuracy in identifying ventricular tachycardia origins. CEO David Jenkins highlighted that the acceptance of abstracts at the conference, which saw record submissions, validates the company's research and the benefits of its technology for the EP community.

•6mo ago

Catheter Precision Secures U.S. Patent Allowance on Foundational Surgical Technology, Establishing Powerful IP and Accelerating Scalable Growth Strategy

Catheter Precision received a Notice of Allowance from the USPTO for key claims covering its proprietary surgical vessel closing pressure device. The protection covers both core device architecture and method of use, establishing a comprehensive IP position for this foundational component. CEO David Jenkins stated the milestone underscores the company's commitment to innovation and strengthens its foundation for long-term shareholder value.

•6mo ago